Significance and Regional Dependency of Peptide Transporter (PEPT) 1 in the Intestinal Permeability of Glycylsarcosine: In Situ Single-Pass Perfusion Studies in Wild-Type and Pept1 Knockout Mice

Dilara Jappar, Shu-Pei Wu, Yongjun Hu, and David E. Smith

Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan

Received April 19, 2010; accepted July 21, 2010

ABSTRACT:
The purpose of this study was to evaluate the role, relevance, and regional dependence of peptide transporter (PEPT) 1 expression and function in mouse intestines using the model dipeptide glycylsarcosine (GlySar). After isolating specific intestinal segments, in situ single-pass perfusions were performed in wild-type and Pept1 knockout mice. The permeability of $[^3H]$GlySar was measured as a function of perfusate pH, dipeptide concentration, potential inhibitors, and intestinal segment, along with Pept1 mRNA and protein. We found the permeability of GlySar to be saturable ($K_m = 5.7 \text{ mM}$), pH-dependent (maximal value at pH 5.5), and specific for PEPT1; other peptide transporters, such as PHT1 and PHT2, were not involved, as judged by the lack of GlySar inhibition by excess concentrations of histidine. GlySar permeabilities were comparable in the duodenum and jejunum of wild-type mice but were much larger than that in ileum (approximately 2-fold). A PEPT1-mediated permeability was not observed for GlySar in the colon of wild-type mice (<10% residual uptake compared to proximal small intestine). Moreover, GlySar permeabilities were very low and not different in the duodenum, jejunum, ileum, and colon of Pept1 knockout mice. Functional activity of intestinal PEPT1 was confirmed by real-time polymerase chain reaction and immunoblot analyses. Our findings suggest that a loss of PEPT1 activity (e.g., due to polymorphisms, disease, or drug interactions) should have a major effect in reducing the intestinal absorption of di-/tripeptides, peptide similarity, and peptide-like drugs.

Introduction

In the gastrointestinal lumen, proteins are converted into large peptides by gastric and pancreatic proteases, which subsequently undergo further hydrolysis into small peptides (80%) and free amino acids (20%) by various peptidases in the brush border membrane of intestinal epithelia (Ganapathy et al., 2006). The final end products of protein digestion are absorbed into the enterocytes predominantly in the form of di-/tripeptides as opposed to free amino acids. Peptide transporter (PEPT) 1, a proton-coupled oligopeptide transporter (POT) with high capacity and low affinity, is believed to be the primary mechanism by which these small peptides enter the cell. Once inside the enterocyte, the majority of di-/tripeptides undergo further hydrolysis into their constituent amino acids by cytoplasmic peptidases and exit the epithelial cells by a distinct family of basolateral amino acid transporters. Those small peptides that are resistant to cytoplasmic peptidases may exit the enterocytes intact by crossing the basolateral membrane via a peptide transporter that has yet to be cloned.

The POTs are membrane proteins that are responsible for translocating di-/tripeptides across biological membranes via an inwardly directed proton gradient and negative membrane potential (Rubio-Aliaga and Daniel, 2002; Daniel and Rubio-Aliaga, 2003; Herrera-Ruiz and Knipp, 2003; Daniel and Kottra, 2004). Thus far, four members of the POT family, specifically PEPT1 (SLC15A1), PEPT2 (SLC15A2), PHT1 (SLCA4), and PHT2 (SLCA3), have been cloned in mammals. In the intestine, PEPT1 functions at the apical membrane by mediating the electrogenic uphill transport of substrates and downhill transport of protons into epithelial cells (i.e., tertiary-active carrier). The driving force for this proton gradient is established by an apical Na⁺/H⁺ antiporter (i.e., secondary-active carrier), whereas the driving force for the inwardly directed sodium gradient is established by Na⁺/K⁺-ATPase, located at the basolateral membrane of intestinal epithelia (i.e., primary-active carrier). In addition to the nutritional role of absorbing nitrogen in the form of di-/tripeptides, PEPT1 transports a number of peptide-like therapeutic agents such as β-lactam antibiotics, angiotensin-converting enzyme inhibitors, renin inhibitors, bestatin, and the antiviral prodrug valacyclovir (Brandsch et al., 2008; Rubio-Aliaga and Daniel, 2008). Due to its broad substrate specificity and high capacity, PEPT1 is considered an attractive target for drug delivery strategies aimed at improving the bioavailability of poorly permeable drugs.

ABBREVIATIONS: PEPT, peptide transporter; POT, proton-coupled oligopeptide transporter; GlySar, glycylsarcosine; PCR, polymerase chain reaction; HRP, horseradish peroxidase; $P_{\text{eff}}$, effective permeability; PHT, peptide/histidine transporter; DMA, dimethylamiloride.
PEPT1 is the most extensively studied transporter among the POT members because of its physiological and pharmacological importance in the absorption of di-/tripeptides and peptide-like drugs from small intestine. However, most of the previous information regarding PEPT1 structure-function and significance was obtained from in vitro studies such as brush border membrane vesicles, cell cultures, and Xenopus oocytes, all of which use nonphysiological conditions that lack blood flow. It should also be appreciated that other POT family members are expressed in the intestine. For example, PEPT2 is found in glial cells and in tissue-resident macrophages of the enteric nervous system (Rühle et al., 2005). Moreover, the peptide/histidine transporters PHT1 and PHT2 have been found in intestinal tissue segments (Herrera-Ruiz et al., 2001), and immunohistochemical analyses have indicated that PHT1 is expressed in the villous epithelium of small intestine (Bhardwaj et al., 2006). However, the functional significance of PEPT2, PHT1, and PHT2 in the intestinal absorption of peptides/mimetics and peptide-like drugs is uncertain.

Heterogeneity has been observed in the intestinal expression of PEPT1 in mice and humans. Immunolocalization studies demonstrated that PEPT1 was expressed in the apical membrane of enterocytes in the small intestine (i.e., duodenum, jejunum, and ileum) of both species with little or no expression in normal colon (Walker et al., 1998; Gronenberg et al., 2001). Whether PEPT1 activity agrees with its expression levels in various intestinal segments is still unknown. This heterogeneity, along with the existence of multiple peptide transport systems with overlapping substrate specificity, makes it difficult, if not impossible, to define the function and significance of a single specific gene product.

A recent article by Hu et al. (2008) described for the first time the development of Pept1 null mice and their preliminary validation and phenotypic analysis in intestine. However, this study was limited in that the functional activity of glycylysarcosine (GlySar) was examined at only one concentration and pH value, and only in jejunal tissue. As a result, the objective of the current study was to define the significance and regional dependence of PEPT1 in the intestinal permeability of GlySar in wild-type and Pept1 knockout mice. Using an in situ single-pass perfusion method, radiolabeled GlySar was studied as a function of perfusate pH, dipeptide concentration, potential inhibitors, and regional segment (i.e., duodenum, jejunum, ileum, and colon). The intestinal expression of PEPT1 mRNA and protein was also evaluated in these segments.

Materials and Methods

Animals. Mouse studies were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health (Institute of Laboratory Animal Resources, 1996). Gender-matched 8- to 10-week-old Pept1(+/+) (wild-type) and Pept1(−/−) (knockout) mice were used for all experiments. The mice were kept in a temperature-controlled environment with 12-h light/dark cycles and received a standard diet and water ad libitum (Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI).

Chemicals. [3H]GlySar (0.5 Ci/mmol) was purchased from Moravek Biochemicals and Radiochemicals (Brea, CA), and [14C]PEG-4000 (1.5 mCi/g) was purchased from American Radiolabeled Compounds (St. Louis, MO). Unlabeled PEG-4000 was obtained from Mallinckrodt Baker, Inc. (Phillipburg, NJ). Acyclovir and valacyclovir were generous gifts from GlaxoSmithKline (Research Triangle Park, NC). All other chemicals were acquired from Sigma-Aldrich (St. Louis, MO).

In Situ Single-Pass Intestinal Perfusion. Intestinal perfusion experiments were performed on wild-type and Pept1 knockout mice according to methods described previously (Adachi et al., 2003; Hu et al., 2008). In brief, animals were fasted overnight with free access to water before each experiment. After anesthesia with sodium pentobarbital (40–60 mg/kg i.p.), surgery was performed on each animal while lying on top of a heating pad to maintain the body temperature. Isopropyl alcohol was used to sterilize the abdominal area, and a 1.5-cm midline incision was made longitudinally to expose the small intestine. An 8-cm segment of proximal jejunum was isolated (i.e., −2 cm distal to the ligament of Treitz), and incisions were then made at the proximal and distal ends. Glass cannulas (2.0 mm outer diameter), attached to Tygon tubing, were inserted at each end of the jejunal segment and secured in place with silk sutures. After cannulations, the isolated intestinal segment was covered with saline-wetted gauze and parafilm to prevent dehydration of the tissue. The animals were then transferred to a temperature-controlled Plexiglas perfusion chamber (31°C) to maintain body temperature during the perfusion experiment. The inlet tubing was connected to a 10-ml syringe placed on a perfusion pump (model 22; Harvard Apparatus, South Natick, MA), and the outlet tubing was placed in a collection vial.

The perfusate (pH 6.5) contained 10 mM MES, 135 mM NaCl, 5 mM KCl, 10 μM [3H]GlySar, and 0.01% (w/v) [14C]PEG-4000, in the absence and presence of potential inhibitors, which flowed through the proximal jejunal segment at a rate of 0.1 ml/min. Exiting perfusate was collected every 10 min for 90 min. A 100-μl aliquot of perfusate was added to 5.5 ml of scintillation cocktail (Ecolite; MP Biomedicals, Solon, OH), and the samples were analyzed with a dual-channel liquid scintillation counter (Beckman LS 6000 SC; Beckman Coulter Inc., Fullerton, CA). [3H]GlySar, a hydrolysis-resistant dipeptide, was added to perfusate as a model substrate, and [14C]PEG-4000 was added to perfusate as a nonabsorbable marker to measure water flux. For pH-dependent analyses, different combinations of 10 mM MES/Tris or HEPEs/Tris were used in perfusate to adjust pH values between 5.0 and 7.4, with osmolality being held constant.

Regional Intestinal Permeability. Simultaneous perfusions, as described previously in rats (Jeong et al., 2006), were adapted for our studies in wild-type and Pept1 knockout mice. Before cannulations of different intestinal segments, the common bile duct was ligated by silk suture. A 2-cm segment of duodenum (i.e., −0.25 cm distal to the pyloric sphincter), 8-cm segment of jejunum (i.e., −2 cm distal to the ligament of Treitz), 6-cm segment of ileum (i.e., −1 cm proximal to the cecum), and 3-cm segment of colon (i.e., −0.5 cm distal to the cecum) were then perfused as described above for jejum alone.

TaqMan Real-Time Polymerase Chain Reaction Analyses. Quantification of PEPT1 transcripts were carried out in different segments of small and large intestines from wild-type mice using the 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA) (Hu et al., 2008). The total RNA was isolated using an RNeasy Plus Mini Kit (QIAGEN, Valencia, CA) and then reverse-transcribed. Primers and probes were designed with Primer Express 3.0 software (Applied Biosystems), and all the primers, probes, and standard DNA were synthesized by Integrated DNA Technologies, Inc. (Corvallis, OR). The forward and reverse primers and probe for PEPT1 were CTGGGACGCACACCAATGG, ACAGAATTCATTGACCACGATGA, and 5′-5′FAM- TTGCTCTCGGTTACCCCGTGGACTC-3′/5′TAMPSp-3′, respectively. The forward and reverse primers and probe for glyceraldehyde 3-phosphate dehydrogenase were GACGACGACGGCATTCCTTGG, CACAGCGACCTTCAACATTGTT and 5′-5′FAM-CTTGCCAGGCTCGCCGTGTA-3′/5′TAMPSp-3′, respectively. The thermal profile was 1 cycle at 50°C for 2 min, 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C for 1 min. The absolute amount of PEPT1 transcripts was calculated automatically based on the standard curve and then normalized by glyceraldehyde 3-phosphate dehydrogenase transcript expression.

Immunoblot Analyses. Mucosa was scraped off the different segments of small and large intestine from wild-type mice and homogenized in 2 ml of Nonidet P40-lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P40, proteinase inhibitor cocktail, pH 8.0). The homogenate was then centrifuged at 15,000g for 5 min at 4°C, and the suspension was sonicated for 10 pulses at one-half strength, followed by a second centrifugation at 15,000g for 5 min at 4°C. The final protein concentration was measured using BCA Protein Assay kit (Pierce, Rockford, IL). The proteins were denatured at 40°C for 45 min, separated by 7.5% SDS-polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA), and then blotted for 1 h with rabbit anti-mouse PEPT1 antiserum (raised against the COOH-terminal region, KGIGKENPYSSLEPVSQTNM, amino acids 690–709; Lampire Biological Laboratories, Inc., Pipertsville, PA) (1:3000) (Hu et al., 2008). The membrane was washed three times with Tris-buffered saline and Tween 20 and then incubated with a secondary antibody, goat anti-rabbit...
IgG conjugated to horseradish peroxidase (HRP) (Bio-Rad, Hercules, CA) (1:1000), for 1 h. For β-actin, the membrane was blotted with a mouse monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) (1:1000) followed by the secondary antibody, goat anti-mouse IgG conjugated to HRP (Santa Cruz Biotechnology) (1:1000). The membranes were then washed five times with TBS-T buffer, and bound antibody was detected with Immobilon Western Chemiluminescent HRP Substrate (Millipore).

**Data Analysis.** The effective permeability ($P_{eff}$) was determined from the steady-state loss of drug from the perfusate as it flows through the intestine, according to a complete radial mixing (parallel tube) model (Komiya et al., 1980; Kou et al., 1991).

$$P_{eff} = \frac{-Q \cdot \ln(C_{in}/C_{out})}{2\pi RL}$$

(1)

In eq. 1, $Q$ is the perfusate flow rate, $R$ is the intestinal radius (0.1 cm), $L$ is the length of intestine, $C_{in}$ is the inlet drug concentration, and $C_{out}$ is the outlet drug concentration (corrected for water flux). Preliminary studies indicated that $[3H]$GlySar was stable in outlet perfusate samples, as determined by high-performance liquid chromatography with radiochemical detection (Ocheltree et al., 2005), thereby alleviating the need for additional corrections to $C_{out}$. In our studies, steady-state was reached at 20 to 30 min after the start of perfusion. The steady-state flux ($J$) across the intestinal membrane was then used to determine the kinetic parameters ($V_{max}$ and $K_m$) when referenced to inlet drug concentrations ($C_{in}$) as shown in eq. 2.

$$J = \frac{V_{max} \cdot C_{in}}{K_m + C_{in}}$$

(2)

Parameter estimates ($V_{max}$ and $K_m$) were also determined after factoring out the resistance across the unstirred water layer (i.e., using a modified boundary layer analysis) (Johnson and Amidon, 1988), and the steady-state flux ($J$) was referenced to intestinal wall concentrations ($C_w$) as shown in eq. 3.

$$J = \frac{V_{max} \cdot C_w}{K_m + C_w}$$

(3)

The relationship between intestinal wall and inlet drug concentrations is shown in eq. 4, where $P_{sw}$ is the unstirred aqueous layer permeability.

$$C_w = C_{in} \left(1 - \frac{P_{eff}}{P_{sw}}\right)$$

(4)

The unstirred aqueous layer permeability was determined according to eqs. 5 and 6:

$$P_{sw} = \left(\frac{R}{A_D Gz^{1/3}}\right)^{-1}$$

(5)

$$Gz = \frac{\pi DL}{2Q}$$

(6)

where $D$ is the aqueous diffusion coefficient (6.60 $\times$ 10$^{-4}$ cm$^2$/min), calculated according to the Hayduk-Laude expression (Reid et al., 1977), $Gz$ is the Graetz number (0.0829), and $A$ is a unitless constant (1.332) estimated by $A = 2.5 Gz + 1.125$.

The flux eqs. 2 and 3 were modeled using a single saturable process (i.e., Michaelis-Menten), where $V_{max}$ (or $V_{max}^*$) is the maximal flux and $K_m^*$ (or $K_m$) is the Michaelis constant. The unknown kinetic parameters were then estimated by nonlinear regression. Other models, such as a single saturable process plus linear term and two saturable processes, were evaluated but did not improve the fit.

**Statistical Analysis.** Data were reported as mean $\pm$ S.E. A two-tailed Student’s $t$ test was used to compare statistical differences between two groups. For multiple comparisons, one-way analysis of variance was used followed by Dunnett’s test for pairwise comparisons with the control group (GraphPad Prism 4.0; GraphPad Software, Inc., La Jolla, CA). A probability of $p \leq 0.05$ was considered significant. Nonlinear regression analyses were performed using GraphPad Prism software, where the quality of fit was determined by evaluating the coefficient of determination ($r^2$), the S.E. of parameter estimates, and by visual inspection of the residuals.

**Results.**

**pH-Dependent Studies.** The effective permeability of 10 μM $[3H]$GlySar was evaluated at various pH values to examine the proton-dependent jejunal uptake of GlySar by PEPT1. As demonstrated in Fig. 1A, there was a minor but statistically significant influence of pH on GlySar permeability in wild-type mice, with the optimal uptake being at pH 5.5. To further examine this relationship, increasing concentrations of dimethylamiloride (DMA), a Na$^+/H^+$ exchange inhibitor (Arakawa and Hara, 1999; Mirossay et al., 1999), were added to perfusate containing GlySar to disrupt the naturally occurring proton gradient. As observed in Fig. 1B, DMA decreased the jejunal permeability of GlySar in wild-type mice in a dose-dependent manner. In contrast, pH had no effect on GlySar permeability in Pept1 knockout (−/−) mice (C). Data are expressed as mean $\pm$ S.E. ($n = 4$).
Concentration-Dependent Studies. To determine the saturability of Pept1 in jejunum, the uptake of $[^{3}H]$GlySar was evaluated at various concentrations of dipeptide (i.e., 0.01–200 mM total substrate in perfusate) in wild-type mice. As observed in Fig. 2A, GlySar exhibited a nonlinear flux that could be described by Michaelis-Menten kinetics, where $V_{\text{max}} = 4.4 \pm 0.2 \text{ mmol/cm}^2/\text{s}$ and $K_{m} = 19.8 \pm 3.3 \text{ mM} \,(r^2 = 0.921)$. When intestinal wall concentrations were used as a reference (i.e., adjusting for the unstirred water layer), the intrinsic absorption parameters were estimated as $V_{\text{max}} = 4.0 \pm 0.2 \text{ mmol/cm}^2/\text{s}$ and $K_{m} = 5.7 \pm 1.1 \text{ mM} \,(r^2 = 0.916)$ (Fig. 2B). These results demonstrate that GlySar was transported in a low-affinity manner, reflective of that for Pept1.

Inhibition Studies. Specificity of the peptide-mediated uptake of 10 mM $[^{3}H]$GlySar was examined in mice by adding a wide range of potential inhibitors to the perfusate during jejunal perfusions. As depicted in Fig. 3A, GlySar permeability was significantly reduced in wild-type mice by several dipeptides (GlySar, GlyPro, and carnosine), the angiotensin-converting enzyme inhibitor captopril, the angiotensin-converting enzyme inhibitor captopril, the decapeptide angiotensin-converting enzyme inhibitor captopril, and the active antiviral prodrug valacyclovir. In contrast, the single amino acids glycine and histidine, the decapeptide angiotensin-converting enzyme inhibitor captopril, and the active antiviral prodrug valacyclovir, were not involved in the intestinal permeability of this dipeptide.

Regional Dependence for Pept1 Activity. To assess whether differences existed in the functional activity of Pept1 along the intestine, GlySar permeability was evaluated in the small and large intestines of wild-type and Pept1 knockout mice. As shown in Fig. 4, GlySar permeabilities were substantially lower in the duodenum, jejunum, and ileum of Pept1 knockout mice compared to wild-type animals. In contrast, GlySar permeability was comparable between genotypes in mouse colon and was not any different between the intestinal segments of Pept1 knockout mice. When GlySar permeabilities were compared among the intestinal segments of wild-type mice, dipeptide permeabilities were comparable in duodenum and jejunum, whereas ileal permeability was ~54% of that in jejunal or duodenal segments. The permeability of GlySar in colon was only 6% of that observed in the jejunum or duodenum.

Specificity of Pept1 was also evaluated in various segments of the intestine. As demonstrated in Fig. 5, copерfusion of GlyPro or cephalosporin cefadroxil substantially decreased the permeability of GlySar in duodenum [by 52% for cefadroxil ($p > 0.05$) and 68% for GlyPro], jejunum (by 72% for cephalosporin and 78% for GlyPro), and ileum (by 58% for cephalosporin and 89% for GlyPro), but not in colon. However, in the presence of histidine, GlySar permeability was unaltered in any of the intestinal segments of wild-type or Pept1 knockout mice.

FIG. 2. Concentration-dependent flux of $[^{3}H]$GlySar (0.01–20 mM total substrate) during jejunal perfusions of wild-type mice. Studies were performed in pH 6.5 perfusion buffer. Data are expressed as mean ± S.E. ($n = 4$). $C_{w}$ represents the perfusate concentration of GlySar (A), whereas $C_{r}$ represents the mean “estimated” concentration of GlySar at the intestinal wall (B).

FIG. 3. Effect of potential inhibitors (25 mM except where noted) on the $P_{\text{eff}}$ of 10 mM $[^{3}H]$GlySar during jejunal perfusions of wild-type (+/+; A) or Pept1 knockout mice (−/−; B). Studies were performed in pH 6.5 perfusion buffer. Data are expressed as mean ± S.E. ($n = 4$). **, $p \leq 0.01$ compared to control values.

FIG. 4. $P_{\text{eff}}$ of 10 mM $[^{3}H]$GlySar in the duodenum, jejunum, ileum, and colon of wild-type (+/+; A) and Pept1 knockout (−/−; B) mice. Studies were performed in pH 6.5 perfusion buffer. Data are expressed as mean ± S.E. ($n = 4–8$). ##, $p \leq 0.01$ and ###, $p \leq 0.001$ compared to both the duodenum and jejunum of wild-type mice; no differences were observed between the intestinal segments of Pept1 knockout mice. ***, $p \leq 0.001$ when comparing Pept1 knockout mice and wild-type animals for a specific intestinal segment.
intestinal segments, demonstrating that PHT1/PHT2 was not involved in dipeptide uptake.

**Regional Dependence for PEPT1 Expression.** The functional activity of intestinal PEPT1 was confirmed by real-time PCR and immunoblot analyses. As shown in Fig. 6, the highest expression of PEPT1 transcripts was found in the jejunum followed by ileum, duodenum, and proximal colon. When evaluated at the protein level (Fig. 7), the strongest staining of PEPT1 was found in jejunum followed by distal colon. No PEPT1 protein was detected in the colon. It is interesting to note that although PEPT1 transcripts were found in distal colon, it did not translate to PEPT1 protein expression in this segment.

**Discussion**

The recent generation of Pept1 knockout mice has provided a unique opportunity to probe the functional activity of PEPT1 under physiological conditions (Hu et al., 2008). Although these authors examined the in situ permeability of GlySar from intestine, their phenotypic analysis was more preliminary in nature. In particular, they only evaluated GlySar at a single concentration and pH value, and permeability was evaluated in jejunal tissue alone as was PEPT1 protein. Other intestinal regions of the mice were neither examined for PEPT1 functional activity nor protein expression. Because of these limitations, we combined in situ permeability studies of GlySar and immunoblot analyses to compare dipeptide transport with PEPT1 protein expression in specific regions of the small intestine and colon.

In this study, we report several new findings regarding the in situ transport properties of GlySar in wild-type versus Pept1 knockout mice and further validate these mice as a model to explore PEPT1 physiology and pharmacology. In particular, we found the following: 1) jejunal permeability of GlySar was saturable in wild-type mice with a low-affinity Km of 5.7 mM; 2) GlySar permeability was specific for PEPT1; 3) functional activity of PEPT1 was highest in wild-type duodenum ≈ jejunum > ileum, with abundant protein expression in these same intestinal regions; 4) PEPT1 was not functionally active in the colon, which is consistent with its lack of protein expression in wild-type proximal or distal colon; 5) GlySar permeabilities were not different among the intestinal segments of Pept1 null mice; and 6) residual uptake of GlySar was less than 10% in duodenum (or jejunum) when comparing Pept1 null to wild-type animals. Taken as a whole, our studies show that PEPT1 has substantial activity along the entire length of mouse small intestine (but not colon), and that dipeptide permeability agrees with the expression levels of PEPT1 protein in these regions.

The pH-dependent transport activity of PEPT1 has been demonstrated in a variety of in vitro models, including rabbit intestinal brush border membrane vesicles (Ganapathy and Leibach, 1983; Ganapathy et al., 1984; Inui et al., 1988), Xenopus oocytes expressing rabbit (Fei et al., 1994), rat (Saito et al., 1995), human (Liang et al., 1995) and mouse (Fei et al., 2000) PEPT1, and cultured Caco-2 cells (Matsumoto et al., 1994; Terada et al., 1999). As shown in these studies, and when stably transfected in Chinese hamster ovary cells (Fujisawa et al., 2006), PEPT1 transport activity versus medium pH displayed a bell-shaped curve with an uptake maximum at pH 5.5 to 6.0. In our in situ studies, GlySar permeability was significantly greater at pH 5.5 (see Fig. 1A). However, the difference (approximately 36%) was not as remarkable as typically observed in other in vitro models. This result is most likely due to fact that changes in luminal bulk pH do not translate into similar changes in pH at the membrane surface of intact animals where the "acid-microclimate" is maintained during in situ or in vivo conditions (Lucas 1983). As shown by Högerle and Winne (1983), the microclimate jejunal pH varied from only 6.0 to 6.5 at the membrane surface even when the luminal bulk pH was raised from 5.0 to 7.4. Still, the pH dependence of PEPT1 activity was confirmed by our studies with DMA (see Fig. 1B), which presumably interfered with the ability of Na"/H" exchanger 3 to acidify the luminal microclimate (Brandsch et al., 2008; Rubio-Aliaga and Daniel, 2008), thereby reducing the intestinal permeability of GlySar.

Human and mouse PEPT1 share many similarities, suggesting that our findings in mice should be relevant in predicting PEPT1-mediated processes in humans. At the molecular level, PEPT1 is highly homologous across species, having an amino acid identity of 83% between...
ROLE OF MOUSE PEPT1 IN GLYSAR INTESTINAL PERMEABILITY

1745

Humans (Liang et al., 1995) and mice (Fei et al., 2000). The genomic organization of human PEPT1 also shows high similarity with its mouse ortholog (Urtti et al., 2001). Functionally, as demonstrated in Xenopus oocytes or cell cultures, the transport properties of human and mouse PEPT1 are similar with respect to driving forces (i.e., stimulated by proton gradient and inside-negative membrane potential), substrate specificity, and substrate affinity (Liang et al., 1995; Fei et al., 2000). In regard to expression, PEPT1 is found in the small intestine and kidney of both species (Liang et al., 1995; Liu et al., 1995; Fei et al., 2000; Shen et al., 2003; Hu et al., 2008). Immunolocalization studies further place PEPT1 at the apical membrane of small intestine (i.e., duodenum, jejunum, and ileum), with little or no expression in the colon of humans and mice (Walker et al., 1998; Groneberg et al., 2001; Ford et al., 2003). Finally, gene expression studies show that both species have comparative intestinal expression patterns and levels, unlike that of the rat (Kim et al., 2007; Rubio-Aliaga and Daniel, 2008).

PEPT1 is a low-affinity, high-capacity transporter with apparent affinities (Km values) ranging from 0.2 to 10 mM, depending upon the substrate, species, tissue cell types, and experimental conditions such as buffer pH (Rubio-Aliaga and Daniel, 2002; Brandsch et al., 2008). The apparent affinity constants of GlySar are in the medium range of substrates, with Km values of approximately 0.5 to 1.5 mM. Under our conditions of study (i.e., in single-pass jejunal perfusion in mice), the intrinsic Km of GlySar was estimated at 5.7 mM. This value is similar to other PEPT1 substrates, namely cefadroxil, cephalixin, and cephradine, where the intrinsic Km values were 5.9, 7.2, and 1.5 mM, respectively, using an in situ single-pass jejunal perfusion technique in rats (Sinko and Amidon, 1988). In both studies (this study and that of Sinko and Amidon, 1988), these Km values are “uninhibited” membrane parameters that have already factored out resistance across the unstirred aqueous boundary layer. In contrast, the Km of GlySar in mouse PEPT1 cRNA-injected Xenopus oocytes was approximately 0.7 mM at -50 mV (Fei et al., 2000). The apparent discrepancy between the two GlySar studies probably reflects differences in experimental design in which one study used an in vitro model (i.e., Xenopus oocytes) lacking in both blood flow and luminal residence times, whereas another study (this one) used a more physiologically based in situ intestinal perfusion model in mice.

Digestion of proteins in the intestinal lumen may yield di-/tripeptide concentrations as high as 100 mM (Ganapathy et al., 2006). Thus, having a low-affinity, high-capacity transporter such as PEPT1 in this region makes physiological sense. As observed in the current study, having a greater PEPT1 activity in the duodenum and jejunum over ileum is also physiologically sound because this POT protein has a reciprocal relationship with both peptidases and amino acid transporters along the small intestine. As the luminal contents move from the proximal to distal small intestine, the concentrations of di-/tripeptides gradually decrease and the concentrations of free amino acids gradually increase, thereby enhancing the efficiency of nutrient absorption.

Previous in vitro studies have shown that human PEPT1, in addition to recognizing di-/tripeptides, also recognizes peptidomimetic thera- peutic agents such as captopril, aminocapshotolin antibiotics, and the antiviral prodrug valacyclovir (Brandsch et al., 2008; Rubio-Aliaga and Daniel, 2008). Our findings, using an in situ mouse intestinal perfusion model, were consistent with those studies regarding the substrate specificities of PEPT1. It is important to note that histidine, a known PHT1/PHT2 substrate, did not inhibit the permeability of GlySar in duodenal, jejunal, ileal, or colonic segments. This finding demonstrates that, despite their presence, the peptide/histidine transporters do not contribute to GlySar’s uptake from the small and large intestines. It has already been confirmed that in Pept1 null mice, other intestinal POT transporters, such as PEPT2, PHT1, and PHT2, do not exhibit a compensatory up-regulation in response to Pept1 gene deletion (Hu et al., 2008).

In conclusion, our study provides the first comprehensive evaluation of the role, relevance, and regional dependence of PEPT1 expression and function in mouse intestines. The results demonstrate that PEPT1 protein is abundantly expressed along the entire length of small intestine with no expression in colon. The expression levels are corroborated by substantial PEPT1 activity in these same intestinal regions, as judged by GlySar permeability estimates during in situ single-pass perfusions. In comparing wild-type and Pept1 knockout mice, it is clear that PEPT1 deficiency (e.g., a loss of activity due to polymorphisms, disease, or drug interactions) should have a major effect in reducing the intestinal absorption di-/tripeptides, peptidomimetics, and peptide-like drugs. Further studies with clinically relevant drugs (and prodrugs) are warranted and currently underway.

References


Downloaded from aspET Journals on June 21, 2017 dmd.aspetjournals.org


Address correspondence to: Dr. David E. Smith, Department of Pharmaceutical Sciences, University of Michigan, 4742 Medical Sciences II, 1150 W Medical Center Drive, Ann Arbor, MI 48109-5633. E-mail: smithb@umich.edu